NIH Won’t Use Industry Money for Opioid Research Initiative

The announcement comes after an agency working group recommends against an industry partnership on ethical grounds.

Written byShawna Williams
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

ISTOCK, MITCHELL WESSELLSThe National Institutes of Health (NIH) will exclusively use taxpayer money for a research initiative on the treatment of pain and substance use disorder, STAT News reports. The announced funding is a shift from what had been touted as a potential public-private partnership, with the federal government and drug companies each contributing approximately $200 million to the initiative.

The change comes after an NIH working group recommended last month that only federal funds be used for planned research aimed at alleviating the opioid crisis. The intent is “[t]o mitigate the risk of real or perceived conflict of interest,” the working group noted. The shift away from using private money for the initiative also comes amid controversy over an NIH agency’s courting of industry funders for a proposed study on the health effects of drinking alcohol.

“There’s so much controversy swirling around pharmaceuticals on the opioid issue,” Rep. Tom Cole (R-Okla.), who chairs the House appropriations subcommittee on health, tells STAT, adding that he agrees with NIH’s decision. An NIH spokesperson tells the outlet that the planned research can proceed with only federal funds ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Shawna was an editor at The Scientist from 2017 through 2022. She holds a bachelor’s degree in biochemistry from Colorado College and a graduate certificate in science communication from the University of California, Santa Cruz. Previously, she worked as a freelance editor and writer, and in the communications offices of several academic research institutions. As news director, Shawna assigned and edited news, opinion, and in-depth feature articles for the website on all aspects of the life sciences. She is based in central Washington State, and is a member of the Northwest Science Writers Association and the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies